453 related items for PubMed ID: 28097746
1. High neutrophil : lymphocyte ratio is associated with refractory Kawasaki disease.
Cho HJ, Bak SY, Kim SY, Yoo R, Baek HS, Yang S, Hwang IT, Ban JE.
Pediatr Int; 2017 Jun; 59(6):669-674. PubMed ID: 28097746
[Abstract] [Full Text] [Related]
2. Value of neutrophil-lymphocyte ratio in predicting outcomes in Kawasaki disease.
Ha KS, Lee J, Jang GY, Lee J, Lee KC, Son CS, Lee JW.
Am J Cardiol; 2015 Jul 15; 116(2):301-6. PubMed ID: 25975725
[Abstract] [Full Text] [Related]
3. [Values of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting sensitivity to intravenous immunoglobulin in Kawasaki disease].
Yuan YD, Sun J, Li PF, Wei CL, Yu YH.
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Apr 15; 19(4):410-413. PubMed ID: 28407827
[Abstract] [Full Text] [Related]
4. The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study.
Kanai T, Takeshita S, Kawamura Y, Kinoshita K, Nakatani K, Iwashima S, Takizawa Y, Hirono K, Mori K, Yoshida Y, Nonoyama S.
Heart Vessels; 2020 Oct 15; 35(10):1463-1472. PubMed ID: 32449049
[Abstract] [Full Text] [Related]
5. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A.
Kardiol Pol; 2017 Oct 15; 75(3):261-266. PubMed ID: 27995598
[Abstract] [Full Text] [Related]
6. A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease.
Takeshita S, Kanai T, Kawamura Y, Yoshida Y, Nonoyama S.
PLoS One; 2017 Oct 15; 12(5):e0176957. PubMed ID: 28542183
[Abstract] [Full Text] [Related]
7. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
PLoS One; 2015 Oct 15; 10(12):e0144603. PubMed ID: 26658843
[Abstract] [Full Text] [Related]
8. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
Ye Q, Gong FQ, Shang SQ, Hu J.
Clin Immunol; 2016 Oct 15; 171():25-31. PubMed ID: 27519954
[Abstract] [Full Text] [Related]
9. Changes in Peripheral Blood Neutrophils, Lymphocytes and IL-10 in Children with Kawasaki Disease from Different Age Groups Undergoing Intravenous Immunoglobulin: A Retrospective Study.
Zhang C, Zhang X, Shen J, Lu X, Zhang J, Chen S.
Mediators Inflamm; 2020 Oct 15; 2020():5213451. PubMed ID: 33293897
[Abstract] [Full Text] [Related]
10. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
Paediatr Int Child Health; 2018 Aug 15; 38(3):209-212. PubMed ID: 29768976
[Abstract] [Full Text] [Related]
11. Value of C-reactive protein/albumin ratio in predicting intravenous immunoglobulin-resistant Kawasaki disease- a data from multi-institutional study in China.
Li G, Wang T, Gou Y, Zeng R, Liu D, Duan Y, Liu B.
Int Immunopharmacol; 2020 Dec 15; 89(Pt A):107037. PubMed ID: 33242833
[Abstract] [Full Text] [Related]
12. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
Turk J Pediatr; 2019 Dec 15; 61(5):648-656. PubMed ID: 32104995
[Abstract] [Full Text] [Related]
13. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
Clin Rheumatol; 2023 Jan 15; 42(1):167-177. PubMed ID: 36129563
[Abstract] [Full Text] [Related]
14. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
Kimura M, Harazaki M, Fukuoka T, Asakura I, Sakai H, Kamimaki T, Ohkawara I, Akiyama N, Tsurui S, Iwashima S, Shimomura M, Morishita H, Meguro T, Seto S.
Pediatr Int; 2017 Apr 15; 59(4):397-403. PubMed ID: 27743415
[Abstract] [Full Text] [Related]
15. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW.
J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390
[Abstract] [Full Text] [Related]
16. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May 15; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
17. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
Wu Y, Liu FF, Xu Y, Wang JJ, Samadli S, Wu YF, Liu HH, Chen WX, Luo HH, Zhang DD, Wei W, Hu P.
Clin Exp Med; 2019 May 15; 19(2):173-181. PubMed ID: 30617865
[Abstract] [Full Text] [Related]
18. The Combined Usefulness of the Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting Intravenous Immunoglobulin Resistance with Kawasaki Disease.
Kawamura Y, Takeshita S, Kanai T, Yoshida Y, Nonoyama S.
J Pediatr; 2016 Nov 15; 178():281-284.e1. PubMed ID: 27526622
[Abstract] [Full Text] [Related]
19. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
[Abstract] [Full Text] [Related]
20. Indicators of unresponsiveness after initial i.v. immunoglobulin treatment in acute Kawasaki disease.
Hashimoto I.
Pediatr Int; 2019 Jul 31; 61(7):641-646. PubMed ID: 31132210
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
